• Bone Transport and TGF-β1 in Diabetic Foot Ulcers

  2026-08-27

  A 2026 rat study identifies TGF-β1/TGFBR1 activation as a mechanistic link between bone transport, angiogenesis, immune regulation, and diabetic foot ulcer repair. By combining proteomics with molecular, histological, and biochemical analyses, the work shows that pathway inhibition substantially weakens the healing response, while also defining important limits for translating the findings to pharmacological workflows.

• Talin1, Piezo1–YAP, and Atherosclerotic Inflammation

  2026-08-26

  A 2026 study identifies Talin1 as a mechanistic link between Piezo1-mediated calcium influx, YAP activation, and inflammatory endothelial responses under atherogenic stress. By combining an ApoE-deficient mouse model with human endothelial-cell experiments, the work suggests that Talin1 may be a more specific target for vascular anti-inflammatory research.

• Gastrodin, RAS–SIRT3, and Reactive Astrocytes

  2026-08-26

  A 2024 European Journal of Neuroscience study examined how gastrodin changes renin–angiotensin system and SIRT3 signaling in astrocytes exposed to activated microglia-conditioned medium. Its main contribution is a cell-to-cell inflammatory model linking AT1 signaling with astrocyte phenotype markers, inflammatory mediators, and neurotrophic responses, while azilsartan provided pharmacological support for an AT1-dependent mechanism.

• EGO-Like Complex Controls TOR in Neurospora

  2026-08-25

  The reference study identifies VTA and GTR2 as components of an amino acid-sensing branch that regulates TOR activity and vacuolar localization in Neurospora crassa. Its comparison of glucose conditions, knockout strains, live-cell imaging, inhibitor treatment, and co-immunoprecipitation provides a framework for connecting nutrient sensing, TORC1 organization, and circadian regulation.

• Losmapimod: p38 MAPK Assay Workflows

  2026-08-25

  Losmapimod enables more than a conventional p38 activity readout: researchers can pair kinase inhibition with activation-loop dephosphorylation assays to test conformationally driven signaling control. This workflow supports inflammation signaling modulation, vascular function improvement, hypertension research, and chronic obstructive pulmonary disease (COPD) research while keeping mechanistic claims experimentally testable.

• hiPSC Sensory Neurons Model HSV-1 Latency

  2026-08-24

  Oh et al. establish a scalable human model in which hiPSCs are rapidly differentiated into excitable sensory neurons that support HSV-1 latency and experimentally induced reactivation. The study combines infectious-virus, transcriptional, latency-associated transcript, and chromatin readouts, creating a useful platform for investigating neuron-intrinsic mechanisms that are difficult to resolve in animal or non-neuronal systems.

• Rocket-Like Nanomedicine Restores PDAC Stroma

  2026-08-23

  Fu et al. developed an acid-responsive, multistage nanomedicine that remodels pancreatic ductal adenocarcinoma stroma before releasing gemcitabine from a mesoporous silica core. In a PDAC mouse model, this stromal homeostasis-restoring strategy produced marked tumor regression without evident treatment-related side effects, while highlighting the translational challenges of moving from stromal ablation to controlled remodeling.

• BMPSB4 Activates Autophagy in Corticotroph PitNETs

  2026-08-22

  The 2024 ACS Pharmacology & Translational Science study identifies BMPSB4 as a BMP4-pathway agonist that suppresses corticotroph pituitary neuroendocrine tumor cells through SMAD1/5/9-dependent autophagy. Its integrated patient-sample, transcriptomic, ultrastructural, cellular, and in vivo evidence provides a mechanistic basis for investigating BMP4 signaling as a therapeutic strategy in Cushing’s disease.

• Dehydroepiandrosterone (DHEA) Research Workflows

  2026-08-21

  Build reproducible DHEA workflows for PCOS, granulosa-cell apoptosis, neural stem-cell growth, and neuroprotection studies. This guide connects solvent handling and exposure design with the CD163-centered ovarian inflammation findings reported in a 2025 reference study.

• Fucoidan and Caveolin-1 in MCF-7 Breast Cancer

  2026-08-20

  A 2026 study identifies caveolin-1 downregulation as a previously underexamined component of Fucoidan activity in MCF-7 breast cancer cells. By combining cytotoxicity, membrane integrity, colony formation, migration, and caveolin-1 assays with tamoxifen comparison, the work connects a marine anticancer polysaccharide to tumor-associated phenotypes while highlighting the need for causal and in vivo validation.

• Astrocytic GAT-3 in Dentate Gyrus Memory

  2026-08-20

  This study identifies astrocytic GAT-3 as an active signaling pathway that converts GABA uptake into calcium-dependent enhancement of dentate gyrus synaptic transmission. Electrophysiological, optogenetic, histological, and behavioral evidence links this pathway to presynaptic GluN2B-containing NMDA receptors and contextual fear memory, while also defining important limits for pharmacological interpretation.

• Digoxin: Applied Cardiac and Antiviral Workflows

  2026-08-19

  Digoxin connects Na+/K+ ATPase inhibition with practical studies of cardiac contractility, arrhythmia biology, heart failure, and cell-specific chikungunya virus responses. This guide turns the product dossier into reproducible workflows, dose-selection logic, and troubleshooting checkpoints while separating established findings from assay-development recommendations.

• Topotecan HCl and the Logic of DNA Damage Selectivity

  2026-08-19

  Topotecan HCl offers a mechanistically precise way to study how DNA damage burden, replication stress, and repair capacity shape tumor response. This thought-leadership guide connects topoisomerase I-DNA complex stabilization with translational oncology strategy, while using recent neuroinflammation findings to sharpen—not overextend—the framework for selective vulnerability.

• Phenytoin and Human PON1: Noncompetitive Inhibition

  2026-08-18

  Beydemir and Demir examined how five antiepileptic drugs inhibit human serum paraoxonase-1 (hPON1) in vitro, combining enzyme purification with concentration-response and kinetic analyses. Phenytoin inhibited hPON1 less strongly than gabapentin, valproic acid, and primidone but more strongly than levetiracetam, while all five compounds showed noncompetitive inhibition under the study conditions.

• Genetically Engineered Mouse Models of Mesothelioma

  2026-08-18

  Kadariya and colleagues present a protocol-centered framework for modeling malignant mesothelioma with genetically engineered mice, linking Bap1, Cdkn2a/b, and Nf2 tumor-suppressor biology to asbestos exposure, inflammation, and therapeutic testing. The review’s main practical contribution is the organization of germline, knock-in, asbestos-induced, and conditional knockout models into experimentally useful workflows that preserve an immunocompetent tumor microenvironment.

441 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page